{"protocolSection":{"identificationModule":{"nctId":"NCT01747746","orgStudyIdInfo":{"id":"12-139"},"organization":{"fullName":"Cook County Health","class":"OTHER_GOV"},"briefTitle":"Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study","officialTitle":"Anticoagulation With Rivaroxaban in Post Cardioversion Patients","acronym":"ARC"},"statusModule":{"statusVerifiedDate":"2015-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-10"},"primaryCompletionDateStruct":{"date":"2014-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10","type":"ACTUAL"},"studyFirstSubmitDate":"2012-11-30","studyFirstSubmitQcDate":"2012-12-11","studyFirstPostDateStruct":{"date":"2012-12-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-02-02","lastUpdatePostDateStruct":{"date":"2015-02-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Pete Antonopoulos","investigatorTitle":"Clinical Pharmacist- Principal Investigator","investigatorAffiliation":"Cook County Health"},"leadSponsor":{"name":"Cook County Health","class":"OTHER_GOV"},"collaborators":[{"name":"Cook County Hospital","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine that a new drug called \"Rivaroxaban®\" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.","detailedDescription":"Patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner). Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K antagonist) the current standard of care in many treatment areas. Rivaroxaban will be compared to Warfarin historical control group studying the safety and efficacy in electrically cardioverted patients."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke","Thrombo-embolism","Bleeding"],"keywords":["Rivaroxaban","Warfarin","Anticoagulation","Stroke","Thrombo-embolism","Bleeding","Atrial Fibrillation","Cardioversion"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":33,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","type":"ACTIVE_COMPARATOR","description":"Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days","interventionNames":["Drug: Rivaroxaban"]},{"label":"Warfarin and Enoxaparin","type":"OTHER","description":"Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control","interventionNames":["Drug: Warfarin and Enoxaparin"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban","description":"Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin","armGroupLabels":["Rivaroxaban"],"otherNames":["Xarelto"]},{"type":"DRUG","name":"Warfarin and Enoxaparin","description":"Historical Control","armGroupLabels":["Warfarin and Enoxaparin"],"otherNames":["Coumadin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Thrombosis","description":"Number of cerebrovascular accidents, thrombus and embolism","timeFrame":"30 days"}],"secondaryOutcomes":[{"measure":"Mortality","description":"Monitor the 30 day mortality rate","timeFrame":"30 days"},{"measure":"Hospitalizations","description":"Hospitalizations for thrombus or adverse events","timeFrame":"30 days"},{"measure":"Bleeding","description":"The incidence of major and minor bleeding (as defined under 'safety measures')","timeFrame":"30 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with non-valvular atrial fibrillation requiring electrical cardioversion o Atrial fibrillation of unknown duration\n\nExclusion Criteria:\n\n* Patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by CHADS2 score ≥ 1\n* Significant renal dysfunction (CrCl \\<15mL/min)\n* Significant hepatic dysfunction (Childs-Pugh Class B or C)\n* History of coagulopathy\n* Active bleeding\n* Hypersensitivity to Rivaroxaban\n* Concomitant use of anticoagulants\n* Concomitant use of potent CYP3A4/P-gp inhibitors or inducers\n* Interventions requiring interruption of therapy\n* Pregnancy\n* Age \\<18 y/o\n* History of GI Bleed","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pete Antonopoulos, PharmD","affiliation":"Cook County Hospital","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Asinul Ansari, MD","affiliation":"Cook County Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Cook County Hospital","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"},{"id":"D000013923","term":"Thromboembolism"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M16372","name":"Thromboembolism","asFound":"Thrombo-Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000017984","term":"Enoxaparin"},{"id":"D000014859","term":"Warfarin"},{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"}],"browseLeaves":[{"id":"M19842","name":"Enoxaparin","asFound":"Professional","relevance":"HIGH"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M136959","name":"Enoxaparin sodium","relevance":"LOW"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}